Miyake Sachiko
Department of Immunology, National Institute of Neuroscience, NCNP, Tokyo, Japan.
Yakugaku Zasshi. 2009 Jun;129(6):649-53. doi: 10.1248/yakushi.129.649.
NKT cells are defined as cells co-expressing of the natural killer receptors such as NK1.1 or NKR-P1A (CD161) and a T cell receptor (TCR). Although NK1.1(+) TCR(+) lymphocytes are heterogeneous, we focus on two distinct T cell subsets express invariant T cell receptor alpha chains, Valpha14-Jalpha18(Valpha14i) and Valpha19-Jalpha33(Valpha19i). Valpha14i NKT cells (Valpha24i NKT cells for human) are restricted by CD1d and Valpha19i NKT cells (Valpha7.2i NKT cells for human) are restricted by MR1 molecule. These cells emerge as an unique lymphocytes subset to bridge innate and acquired immunity. Here in this review, we discuss on the role of these cells in the regulation of autoimmunity and on the potential of therapeutic target for autoimmune diseases.
自然杀伤T细胞(NKT细胞)被定义为共表达自然杀伤受体(如NK1.1或NKR - P1A(CD161))和T细胞受体(TCR)的细胞。尽管NK1.1(+) TCR(+)淋巴细胞具有异质性,但我们关注两个不同的T细胞亚群,它们表达恒定的T细胞受体α链,即Vα14 - Jα18(Vα14i)和Vα19 - Jα33(Vα19i)。Vα14i NKT细胞(人类为Vα24i NKT细胞)受CD1d限制,Vα19i NKT细胞(人类为Vα7.2i NKT细胞)受MR1分子限制。这些细胞作为一种独特的淋巴细胞亚群出现,以连接固有免疫和获得性免疫。在本综述中,我们讨论这些细胞在自身免疫调节中的作用以及作为自身免疫性疾病治疗靶点的潜力。